MA27004A1 - Conjugues de pregabaline et de lactose - Google Patents

Conjugues de pregabaline et de lactose

Info

Publication number
MA27004A1
MA27004A1 MA27315A MA27315A MA27004A1 MA 27004 A1 MA27004 A1 MA 27004A1 MA 27315 A MA27315 A MA 27315A MA 27315 A MA27315 A MA 27315A MA 27004 A1 MA27004 A1 MA 27004A1
Authority
MA
Morocco
Prior art keywords
pregabalin
lactose
conjugates
compounds
compositions
Prior art date
Application number
MA27315A
Other languages
English (en)
Inventor
Timothy Robert Hurley
Brian TOBIAS
Michael James Lovdahl
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA27004A1 publication Critical patent/MA27004A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

DEPOSANT Société dite : WARNER-LAMBERT COMPANY LLC REVENDICATION DE PRIORITES US 30 Mars 2001 60/280,176 Voir en annexe le titre de l'invention et le texte de l'abrégé Conjugués de prégabaline et de lactose L'invention a pour objet des composés conjugués de prégabaline et de lactose. Elle concerne également des compositions les contenant. Application : Utilisation de ces composés et compositions pour le traitement de diverses maladies du système nerveux central. (Pas de figure à publier).
MA27315A 2001-03-30 2003-09-17 Conjugues de pregabaline et de lactose MA27004A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28017601P 2001-03-30 2001-03-30

Publications (1)

Publication Number Publication Date
MA27004A1 true MA27004A1 (fr) 2004-12-20

Family

ID=23072002

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27315A MA27004A1 (fr) 2001-03-30 2003-09-17 Conjugues de pregabaline et de lactose

Country Status (32)

Country Link
US (1) US7022678B2 (fr)
EP (1) EP1377318A2 (fr)
JP (1) JP2004524357A (fr)
KR (1) KR20040008146A (fr)
CN (1) CN1511043A (fr)
AP (1) AP2003002873A0 (fr)
AR (1) AR033024A1 (fr)
BG (1) BG108193A (fr)
BR (1) BR0208439A (fr)
CA (1) CA2440468C (fr)
CZ (1) CZ20032547A3 (fr)
DO (1) DOP2002000356A (fr)
EA (1) EA200300954A1 (fr)
EC (1) ECSP034740A (fr)
EE (1) EE200300480A (fr)
GT (1) GT200200051A (fr)
HU (1) HUP0303956A2 (fr)
IL (1) IL157879A0 (fr)
IS (1) IS6912A (fr)
MA (1) MA27004A1 (fr)
MX (1) MXPA03007437A (fr)
NO (1) NO20034348L (fr)
OA (1) OA12456A (fr)
PA (1) PA8542101A1 (fr)
PE (1) PE20021016A1 (fr)
PL (1) PL369179A1 (fr)
SK (1) SK11832003A3 (fr)
SV (1) SV2003000928A (fr)
TN (1) TNSN02038A1 (fr)
UY (1) UY27233A1 (fr)
WO (1) WO2002078747A2 (fr)
ZA (1) ZA200306608B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9710536A (pt) 1996-07-24 1999-08-17 Warner Lambert Co Isobutilgaba e seus derivados para o tratamento da dor
WO2007035890A1 (fr) 2005-09-19 2007-03-29 Teva Pharmaceutical Industries Ltd. Synthese asymetrique de l'acide (s)-(+)-3-(aminomethyl)-5-methylhexanoique
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
KR20100107500A (ko) * 2008-06-23 2010-10-05 테바 파마슈티컬 인더스트리즈 리미티드 (ｓ) 또는 (ｒ)-이소-부틸-글루타릭 에스테르의 입체선택적 효소 합성방법
WO2010115612A2 (fr) 2009-04-10 2010-10-14 Synthon B.V. Compositions de prégabaline
WO2010150221A1 (fr) 2009-06-25 2010-12-29 Wockhardt Research Centre Compositions pharmaceutiques de prégabaline de saveur masquée
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
CN104311608B (zh) * 2014-10-28 2016-10-05 河南中烟工业有限责任公司 亲水型烟草增香保润剂Mal-Hyp、制备方法及其应用
CN104370986B (zh) * 2014-10-28 2017-07-04 河南中烟工业有限责任公司 糖衍生物烟用增香保润剂Mal‑Pro、制备方法及其应用
CN105520918B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊
CN105434395B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
WO2000023067A1 (fr) * 1998-10-16 2000-04-27 Warner-Lambert Company Traitement de la manie et des troubles bipolaires
EP1337271B1 (fr) * 2000-11-30 2004-11-03 Pfizer Products Inc. Combinaison d'agonistes gaba et d'inhibiteurs de la sorbitol-deshydrogenase (sdi)

Also Published As

Publication number Publication date
PA8542101A1 (es) 2002-10-28
EE200300480A (et) 2003-12-15
KR20040008146A (ko) 2004-01-28
CA2440468C (fr) 2008-09-02
WO2002078747A9 (fr) 2003-12-31
US20020187941A1 (en) 2002-12-12
EA200300954A1 (ru) 2004-02-26
WO2002078747A8 (fr) 2003-12-04
HUP0303956A2 (hu) 2004-04-28
JP2004524357A (ja) 2004-08-12
NO20034348D0 (no) 2003-09-29
SK11832003A3 (sk) 2004-04-06
SV2003000928A (es) 2003-07-29
MXPA03007437A (es) 2003-11-18
OA12456A (en) 2004-08-24
GT200200051A (es) 2002-11-15
EP1377318A2 (fr) 2004-01-07
WO2002078747A3 (fr) 2003-10-09
PE20021016A1 (es) 2002-11-14
PL369179A1 (en) 2005-04-18
WO2002078747A2 (fr) 2002-10-10
NO20034348L (no) 2003-09-29
BG108193A (en) 2004-09-30
AP2003002873A0 (en) 2003-09-30
CA2440468A1 (fr) 2002-10-10
IS6912A (is) 2003-08-14
AR033024A1 (es) 2003-12-03
IL157879A0 (en) 2004-03-28
CN1511043A (zh) 2004-07-07
ECSP034740A (es) 2003-12-24
UY27233A1 (es) 2002-10-31
CZ20032547A3 (en) 2004-04-14
BR0208439A (pt) 2004-03-23
US7022678B2 (en) 2006-04-04
TNSN02038A1 (fr) 2005-12-23
ZA200306608B (en) 2004-11-25
DOP2002000356A (es) 2002-12-15

Similar Documents

Publication Publication Date Title
MA27004A1 (fr) Conjugues de pregabaline et de lactose
MA27509A1 (fr) Formulations a liberation prolongee contenant de la lamotrigine
MA27188A1 (fr) Aminoacides a affinite pour la proteine alpha-2-delta
DE69810328D1 (de) Zusammenstellung aus gemischten cyanoacrylatestern
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
MA27181A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar.
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
FR2831818B1 (fr) Composition oxydante pour le traitement des fibres keratiniques comprenant une silicone aminee particuliere
FR2825277B1 (fr) Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
BR9712491A (pt) Composições cosméticas
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2
BR0210481A (pt) Tablete de caldo de carne compacto
BR9812837A (pt) Processo para fazer um composto, e, composto
BR9913225A (pt) Novos agentes antibacterianos de isoxazolinona
FR2806299B1 (fr) Compositions pour la teinture des fibres keratiniques contenant des derives de paraphenylenediamine a groupement pyrrolidinyle
BR9910539A (pt) Derivados de 2 - (2 - clorofenil) - 3,4 - dihidro - 2h - pirrol
BR0207654A (pt) Composição que compreende um creme ou loção base
DK1414473T3 (da) Orale sammensætninger til behandling af hovedbundssygdomme
BR0114912A (pt) Kahalalide f
BR0210543A (pt) Tablete macio de caldo de carne
MA27169A1 (fr) Metabolites de l'acide (3-{ [(4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetique
BR0009211A (pt) Derivados de resorcinol
EP1312348A3 (fr) Utilisation de silicones aminées particulières en pré- ou post-traitement de décoloration de fibres kératiniques
WO2001043705A3 (fr) Compositions a base de retinoides et de stilbenes pour le soin de la peau